Veradigm (MDRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2024, filed May 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDRX SEC filings page.
Veradigm (MDRX) reported $594.4M in revenue for fiscal year 2024, down 5.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Veradigm’s dominant mechanic is cost-base expansion amid softer revenue, turning prior cash generation into operating losses.
Revenue softened while gross margin compressed from54.6% to50.9% , indicating weaker economics per sales dollar rather than a volume-only slowdown. Meanwhile, selling, general and administrative expense expanded from$201M to$269M , exposing a cost structure that became much less adaptable when revenue weakened.
Cash conversion reversed: FY2023 produced positive operating cash flow and free cash flow, but FY2024 reported operating cash flow of
Assets fell to
Financial Health Signals
Veradigm does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Veradigm scores 1.03, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($495.9M) relative to total liabilities ($548.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Veradigm passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Veradigm reported a net loss of $291.5M while operations used $20.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Veradigm reported an operating loss of $194.7M against $15.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Veradigm generated $150.1M in revenue in Q4 2024. This represents a decrease of 2.9% from the same quarter a year earlier. Against the prior quarter it is up 3.4%.
Veradigm's EBITDA was -$222K in Q4 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 103.2% from the same quarter a year earlier. Against the prior quarter it is up 98.1%.
Veradigm reported -$113.6M in net income in Q4 2024. This represents a decrease of 1996.6% from the same quarter a year earlier. Against the prior quarter it is down 365.8%.
Veradigm earned -$1.05 per diluted share (EPS) in Q4 2024. This represents a decrease of 2725.0% from the same quarter a year earlier. Against the prior quarter it is down 356.5%.
Cash & Balance Sheet
Veradigm recorded an outflow of $3.0M in free cash flow in Q4 2024, representing a cash shortfall after capex. This represents a decrease of 115.3% from the same quarter a year earlier. Against the prior quarter it is up 74.0%.
Veradigm held $294.3M in cash against $72.2M in long-term debt as of Q4 2024.
Not reported for Q4 2024.
Margins & Returns
Veradigm's gross margin was 50.0% in Q4 2024, indicating the percentage of revenue retained after direct costs. This is down 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.
Veradigm's operating margin was -7.6% in Q4 2024, reflecting core business profitability. This is down 4.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.3 percentage points.
Veradigm's net profit margin was -75.7% in Q4 2024, showing the share of revenue converted to profit. This is down 79.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 58.9 percentage points.
Veradigm's ROE was -14.1% in Q4 2024, measuring profit generated per dollar of shareholder equity. This is down 14.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.4 percentage points.
Capital Allocation
Veradigm invested $26.4M in research and development in Q4 2024. This represents an increase of 12.8% from the same quarter a year earlier. Against the prior quarter it is down 2.1%.
Veradigm invested $334K in capex in Q4 2024, funding long-term assets and infrastructure. This represents a decrease of 6.2% from the same quarter a year earlier. Against the prior quarter it is up 125.7%.
Not reported for Q4 2024.
MDRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-K | Q2'2410-K | Q1'2410-K | Q4'2310-K | Q3'2310-K | Q2'2310-K | Q1'2310-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $150.1M-2.9% | $145.2M-2.4% | $152.8M-11.8% | $146.4M-2.1% | $154.5M-1.1% | $148.8M+1.6% | $173.2M+16.6% | $149.5M+9.2% |
| Cost of Revenue | $75.0M+6.0% | $72.8M+3.9% | $72.3M-2.0% | $72.0M+3.2% | $70.8M+2.1% | $70.1M+1.0% | $73.8M+2.7% | $69.7M+1.2% |
| Gross Profit | $75.0M-10.4% | $72.4M-8.1% | $80.5M-19.0% | $74.4M-6.7% | $83.7M-3.6% | $78.7M+2.3% | $99.4M+29.7% | $79.7M+17.2% |
| R&D Expenses | $26.4M+12.8% | $27.0M+14.2% | $26.9M+13.4% | $28.0M+6.7% | $23.4M-13.2% | $23.6M-5.7% | $23.8M+2.6% | $26.2M+15.3% |
| SG&A Expenses | $57.2M-8.6% | $65.7M+27.1% | $69.0M+75.3% | $77.5M+63.7% | $62.6M+43.4% | $51.7M+34.1% | $39.4M-7.0% | $47.3M+5.9% |
| Operating Income | -$11.4M-158.3% | -$23.1M-1956.0% | -$24.2M-171.0% | -$136.1M-3663.8% | -$4.4M+53.4% | $1.2M+113.0% | $34.0M+852.6% | $3.8M+207.0% |
| EBITDA | -$222K-103.2% | -$11.5M-183.6% | -$12.6M-126.2% | -$124.6M-772.2% | $7.0M-88.8% | $13.8M+223.3% | $48.0M+388.0% | $18.5M+75.9% |
| Interest Expense | $3.3M+169.2% | $3.7M+150.8% | $3.8M+179.3% | $4.2M+244.2% | $1.2M+13.8% | $1.5M+17.3% | $1.4M-27.7% | $1.2M-42.3% |
| Income Tax | $91.3M+1456.8% | -$2.9M-179.0% | -$1.9M-119.0% | -$17.0M-579.2% | -$6.7M-137.5% | $3.7M+137.0% | $10.1M+136.2% | $3.5M+115.0% |
| Net Income | -$113.6M-1996.6% | -$24.4M-248.1% | -$24.7M-198.4% | -$128.9M-7887.3% | $6.0M+122.6% | $16.5M+3619.2% | $25.1M+130.2% | $1.7M-93.0% |
| EPS (Basic) | -$1.05-1850.0% | -$0.23-253.3% | -$0.23-200.0% | -$1.19-6050.0% | $0.06+124.0% | $0.15+1600.0% | $0.23+131.5% | $0.02-90.0% |
| EPS (Diluted) | -$1.05-2725.0% | -$0.23-264.3% | -$0.23-209.5% | -$1.19-6050.0% | $0.04+116.0% | $0.14 | $0.21+128.8% | $0.02 |
Not reported in any period shown, so not listed: Diluted Shares (Avg).
MDRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-K | Q2'2410-K | Q1'2410-K | Q4'2310-K | Q3'2310-K | Q2'2310-K | Q1'2310-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B-14.0% | $1.5B-7.3% | $1.5B-4.4% | $1.5B-1.7% | $1.6B+4.5% | $1.6B-6.7% | $1.6B-9.1% | $1.5B-36.6% |
| Current Assets | $545.6M-22.0% | $556.9M-22.2% | $586.7M-17.6% | $606.8M-12.8% | $699.2M+2.9% | $716.0M-11.7% | $711.7M-14.1% | $695.6M-54.9% |
| Cash & Equivalents | $294.3M-34.1% | $302.3M-33.7% | $330.7M-29.8% | $343.5M-24.3% | $446.6M0.0% | $455.7M-7.5% | $471.2M-5.8% | $453.9M+448.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $107.6M-3.2% | $114.2M-3.3% | $121.0M+3.8% | $110.9M-3.5% | $111.2M-6.7% | $118.1M-30.1% | $116.6M-30.1% | $114.9M-32.6% |
| Long-Term Investments | $98.7M+0.3% | $104.9M+33.2% | $100.5M+104.0% | $100.1M+103.1% | $98.5M | $78.7M | $49.3M | $49.3M |
| Goodwill | $520.7M-2.2% | $520.7M-2.2% | $520.7M-2.2% | $520.7M-2.2% | $532.5M0.0% | $532.5M+1.6% | $532.5M+1.6% | $532.5M+2.4% |
| Total Liabilities | $548.3M+10.0% | $550.0M+7.5% | $561.5M+10.0% | $565.6M+9.2% | $498.4M+2.3% | $511.4M-0.4% | $510.7M-1.4% | $518.2M-51.9% |
| Current Liabilities | $421.9M-5.4% | $421.0M-7.2% | $427.2M-5.5% | $502.1M+9.4% | $446.0M+93.6% | $453.9M+79.3% | $452.2M+76.4% | $459.1M-29.0% |
| Non-Current Liabilities | $126.4M+141.0% | $129.0M+124.1% | $134.3M+129.6% | $63.6M+7.7% | $52.5M-79.6% | $57.6M-77.9% | $58.5M-77.6% | $59.0M-86.3% |
| Long-Term Debt | $72.2M | $72.2M | $72.2M | $0 | $0-100.0% | N/A | N/A | N/A |
| Total Equity | $804.0M-25.2% | $911.3M-14.5% | $929.2M-11.3% | $950.0M-7.1% | $1.1B+5.6% | $1.1B-9.5% | $1.0B-12.4% | $1.0B-24.4% |
| Retained Earnings | $403.4M-41.9% | $517.1M-25.0% | $541.4M-19.5% | $566.1M-12.6% | $695.0M+7.6% | $689.0M-8.5% | $672.5M-9.0% | $647.5M-19.4% |
Not reported in any period shown, so not listed: Inventory.
MDRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-K | Q2'2410-K | Q1'2410-K | Q4'2310-K | Q3'2310-K | Q2'2310-K | Q1'2310-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M-113.3% | -$11.3M-143.7% | -$20.8M-171.1% | $14.7M-39.6% | $20.0M-5.2% | $26.0M-7.7% | $29.2M+1885.6% | $24.4M-64.8% |
| Depreciation & Amortization | $11.2M-1.8% | $11.5M-7.9% | $11.6M-17.5% | $11.5M-21.8% | $11.4M-84.1% | $12.5M-9.3% | $14.0M-2.4% | $14.7M+4.3% |
| Stock-Based Compensation | N/A | N/A | N/A | $5.8M-7.2% | N/A | N/A | N/A | $6.2M-1.8% |
| Capital Expenditures | $334K-6.2% | $148K-26.4% | $691K+85.8% | $379K-69.8% | $356K+91.4% | $201K-10.3% | $372K-71.5% | $1.3M+263.2% |
| Free Cash Flow | -$3.0M-115.3% | -$11.5M-144.6% | -$21.5M-174.4% | $14.4M-37.9% | $19.6M-6.1% | $25.8M-7.7% | $28.8M+1079.7% | $23.1M-66.4% |
| Investing Cash Flow | -$5.4M+81.0% | -$16.5M+56.9% | $10.3M+243.9% | -$114.1M-675.4% | -$28.2M-51.9% | -$38.3M-313.7% | -$7.1M-101.1% | -$14.7M+66.7% |
| Financing Cash Flow | -$3K+99.7% | -$614K+80.5% | -$2.3M+52.6% | -$3.8M-3.6% | -$894K+98.5% | -$3.1M+91.8% | -$4.8M+98.3% | -$3.6M+94.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MDRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-K | Q2'2410-K | Q1'2410-K | Q4'2310-K | Q3'2310-K | Q2'2310-K | Q1'2310-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.0%-4.2pp | 49.8%-3.1pp | 52.7%-4.7pp | 50.8%-2.5pp | 54.2%-1.4pp | 52.9%+0.3pp | 57.4%+5.8pp | 53.3%+3.7pp |
| Operating Margin | -7.6%-4.7pp | -15.9%-16.7pp | -15.8%-35.4pp | -93.0%-95.5pp | -2.9%+3.2pp | 0.8%+7.4pp | 19.6%+22.7pp | 2.5%+5.2pp |
| Net Margin | -75.7%-79.6pp | -16.8%-27.9pp | -16.1%-30.6pp | -88.1%-89.2pp | 3.9%+20.9pp | 11.1%+11.4pp | 14.5%+70.4pp | 1.1%-16.1pp |
| Return on Equity | -14.1%-14.7pp | -2.7%-4.2pp | -2.6%-5.0pp | -13.6%-13.7pp | 0.6%+3.2pp | 1.6%+1.6pp | 2.4%+9.3pp | 0.2%-1.6pp |
| Return on Assets | -8.4%-8.8pp | -1.7%-2.7pp | -1.7%-3.3pp | -8.5%-8.6pp | 0.4%+2.1pp | 1.0%+1.1pp | 1.6%+6.5pp | 0.1%-0.9pp |
| Current Ratio | 1.29-0.3x | 1.32-0.3x | 1.37-0.2x | 1.21-0.3x | 1.57-1.4x | 1.58-1.6x | 1.57-1.7x | 1.51-0.9x |
| Debt-to-Equity | 0.09+0.1x | 0.08-0.4x | 0.08-0.4x | 0.00-0.5x | 0.00-0.2x | 0.48+0.3x | 0.49+0.3x | 0.51+0.2x |
| Asset Turnover | 0.110.0x | 0.100.0x | 0.100.0x | 0.100.0x | 0.100.0x | 0.090.0x | 0.110.0x | 0.100.0x |
| FCF Margin | -2.0%-14.7pp | -7.9%-25.2pp | -14.0%-30.7pp | 9.8%-5.7pp | 12.7%-0.7pp | 17.3%-1.8pp | 16.6%+18.6pp | 15.5%-34.9pp |
Where Veradigm Ranks
Frequently Asked Questions
What is Veradigm's annual revenue?
Veradigm (MDRX) reported $594.4M in total revenue for fiscal year 2024. This represents a -5.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Veradigm's revenue growing?
Veradigm (MDRX) revenue declined by 5.0% year-over-year, from $626.0M to $594.4M in fiscal year 2024.
Is Veradigm profitable?
No, Veradigm (MDRX) reported a net income of -$291.5M in fiscal year 2024, with a net profit margin of -49.0%.
What is Veradigm's EBITDA?
Veradigm (MDRX) had EBITDA of -$148.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Veradigm have?
As of fiscal year 2024, Veradigm (MDRX) had $294.3M in cash and equivalents against $72.2M in long-term debt.
What is Veradigm's gross margin?
Veradigm (MDRX) had a gross margin of 50.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Veradigm's operating margin?
Veradigm (MDRX) had an operating margin of -32.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Veradigm's net profit margin?
Veradigm (MDRX) had a net profit margin of -49.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Veradigm's return on equity (ROE)?
Veradigm (MDRX) has a return on equity of -36.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Veradigm's free cash flow?
Veradigm (MDRX) recorded an outflow of $21.6M in free cash flow during fiscal year 2024. This represents a -122.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Veradigm's operating cash flow?
Veradigm (MDRX) recorded an outflow of $20.0M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Veradigm's total assets?
Veradigm (MDRX) had $1.4B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Veradigm's capital expenditures?
Veradigm (MDRX) invested $1.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Veradigm spend on research and development?
Veradigm (MDRX) invested $108.3M in research and development during fiscal year 2024.
What is Veradigm's current ratio?
Veradigm (MDRX) had a current ratio of 1.29 as of fiscal year 2024, which is considered adequate.
What is Veradigm's debt-to-equity ratio?
Veradigm (MDRX) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Veradigm's return on assets (ROA)?
Veradigm (MDRX) had a return on assets of -21.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Veradigm's P/E ratio?
Veradigm (MDRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $495.9M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Veradigm's price-to-sales ratio?
Veradigm (MDRX) trades at 0.8x sales, its market capitalization divided by revenue of $594.4M revenue, FY2024. The market capitalization is $495.9M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Veradigm's Altman Z-Score?
Veradigm (MDRX) has an Altman Z-Score of 1.03, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Veradigm's Piotroski F-Score?
Veradigm (MDRX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Veradigm's earnings high quality?
Veradigm (MDRX) reported a net loss of $291.5M while operations used $20.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Veradigm cover its interest payments?
Veradigm (MDRX) reported an operating loss of $194.7M against $15.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.